Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry.
Sebastiani M, Venerito V, Bugatti S, Bazzani C, Biggioggero M, Petricca L, Foti R, Bortoluzzi A, Balduzzi S, Visalli E, Frediani B, Manfredi A, Gremese E, Favalli E, Iannone F, Ferraccioli G, Lapadula G; Contributors. Sebastiani M, et al. Among authors: bugatti s. Clin Rheumatol. 2021 Oct;40(10):4039-4047. doi: 10.1007/s10067-021-05734-3. Epub 2021 Apr 21. Clin Rheumatol. 2021. PMID: 33881676
Long term treatment of rheumatoid arthritis with rituximab.
Caporali R, Caprioli M, Bobbio-Pallavicini F, Bugatti S, Montecucco C. Caporali R, et al. Among authors: bugatti s. Autoimmun Rev. 2009 Jun;8(7):591-4. doi: 10.1016/j.autrev.2009.02.008. Epub 2009 Feb 11. Autoimmun Rev. 2009. PMID: 19393205
Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy.
Caporali R, Conti F, Alivernini S, Atzeni F, Seriolo B, Cutolo M, Valesini G, Ferraccioli G, Sarzi-Puttini P, Salvarani C, Guiducci S, Zampogna G, Gremese E, Pipitone N, Scrivo R, Bugatti S, Montecucco C, Matucci-Cerinic M; Italian Society for Rheumatology. Caporali R, et al. Among authors: bugatti s. Clin Exp Rheumatol. 2011 May-Jun;29(3 Suppl 66):S7-14. Epub 2011 Jul 26. Clin Exp Rheumatol. 2011. PMID: 21906423 Review.
Early treatment in early undifferentiated arthritis.
Olivieri I, Sarzi-Puttini P, Bugatti S, Atzeni F, d'Angelo S, Caporali R. Olivieri I, et al. Among authors: bugatti s. Autoimmun Rev. 2012 Jun;11(8):589-92. doi: 10.1016/j.autrev.2011.10.019. Epub 2011 Oct 20. Autoimmun Rev. 2012. PMID: 22037115 Review.
Long-term safety of abatacept in patients with rheumatoid arthritis.
Atzeni F, Sarzi-Puttini P, Mutti A, Bugatti S, Cavagna L, Caporali R. Atzeni F, et al. Among authors: bugatti s. Autoimmun Rev. 2013 Oct;12(12):1115-7. doi: 10.1016/j.autrev.2013.06.011. Epub 2013 Jun 22. Autoimmun Rev. 2013. PMID: 23800448 Review.
WITHDRAWN: Abatacept as a first-line biological therapy.
Caporali R, Bugatti S, Cavagna L, Antivalle M, Atzeni F, Puttini PS. Caporali R, et al. Among authors: bugatti s. Autoimmun Rev. 2013 Jun 24:S1568-9972(13)00114-6. doi: 10.1016/j.autrev.2013.06.010. Online ahead of print. Autoimmun Rev. 2013. PMID: 23806564
In early inflammatory polyarthritis more intensive management according to the 2010 ACR/EULAR criteria leads to higher rates of clinical remission: comparison of two cohorts treated according to different treat-to-target protocols.
Balduzzi S, Scirè CA, Sakellariou G, Benaglio F, Bugatti S, Montecucco C, Caporali R. Balduzzi S, et al. Among authors: bugatti s. Clin Exp Rheumatol. 2017 May-Jun;35(3):401-405. Epub 2016 Dec 13. Clin Exp Rheumatol. 2017. PMID: 27974097
138 results